KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EBITDA (2017 - 2025)

Historic EBITDA for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to -$68.9 million.

  • Cardlytics' EBITDA rose 5364.8% to -$68.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.0 million, marking a year-over-year increase of 6413.86%. This contributed to the annual value of -$195.5 million for FY2024, which is 4409.89% down from last year.
  • Latest data reveals that Cardlytics reported EBITDA of -$68.9 million as of Q3 2025, which was up 5364.8% from -$12.8 million recorded in Q2 2025.
  • Over the past 5 years, Cardlytics' EBITDA peaked at $35.7 million during Q1 2022, and registered a low of -$382.6 million during Q4 2022.
  • Moreover, its 5-year median value for EBITDA was -$22.2 million (2021), whereas its average is -$53.0 million.
  • The largest annual percentage gain for Cardlytics' EBITDA in the last 5 years was 26083.72% (2022), contrasted with its biggest fall of 223186.06% (2022).
  • Over the past 5 years, Cardlytics' EBITDA (Quarter) stood at -$16.4 million in 2021, then plummeted by 2231.86% to -$382.6 million in 2022, then soared by 73.1% to -$102.9 million in 2023, then skyrocketed by 91.92% to -$8.3 million in 2024, then crashed by 728.17% to -$68.9 million in 2025.
  • Its EBITDA stands at -$68.9 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$14.1 million for Q1 2025.